.svg)
BHRT Therapy is hormone treatment selected for a defined clinical indication—not a general anti-aging therapy. Evaluation focuses on symptoms, medical history, contraindications, and laboratory testing when appropriate before choosing a hormone, dose, and route.
Hormone therapy may improve specific symptoms when those symptoms are related to a documented hormone deficiency or menopausal transition. Concerns involving sexual wellness, mood, sleep, energy, and body composition still require an individualized differential diagnosis rather than assuming hormones are the cause.
Hormone therapy is not a general treatment for weight or metabolic symptoms, fatigue, cognition, or sleep unless evaluation suggests a hormone-related cause. Formulation choice is based on the indication, evidence, route, risks, and patient preference—not on the word “bioidentical” alone.
What Hormone Therapy Evaluation Covers
Hormone therapy begins with confirming the clinical problem, reviewing risks and alternatives, and choosing the formulation and dose with the best evidence for the individual patient.
.webp)
Hormone Therapy: Formulation, Monitoring & Follow-Up
.svg)
.svg)
Why Choose AlyneMD
What to Expect From Your Treatment Journey
Pre-Treatment
Post-Treatment
hydration & protein. Report side effects promptly.
Follow-up labs every 6-8 weeks.
How AlyneMD Chooses Hormone Therapy
Diagnosis Before Replacement
FDA-Approved Formulations First
Route, Dose & Monitoring Matter
Frequently Asked Questions
“Bioidentical” describes hormones that are chemically identical to endogenous hormones; it does not mean a product is automatically safer or more effective. FDA-approved bioidentical options such as estradiol and micronized progesterone exist, while custom-compounded products have different oversight and quality considerations.
Candidacy depends on the clinical indication, symptom pattern, medical history, age, sex, relevant laboratory findings, and contraindications. Fatigue, sleep problems, mood changes, sexual symptoms, and weight changes have many possible causes, so hormone therapy should follow evaluation rather than symptom matching alone.
The plan is based on the indication, symptoms, medical and family history, contraindications, formulation options, and laboratory testing when clinically useful. Route and dose are selected to balance symptom relief with known risks—not simply to reach a target lab number.
Response timing varies by symptom, hormone, route, and dose. Some symptoms may improve within weeks while others take longer; lack of meaningful benefit should prompt reassessment rather than automatic dose escalation.
Risks depend on the hormone, dose, route, age, and medical history. Depending on the regimen, concerns can include bleeding changes, breast symptoms, acne or androgenic effects, erythrocytosis, venous thromboembolism, cardiovascular risk, or other formulation-specific adverse effects. Screening and follow-up are part of treatment.
Cost depends on the evaluation, laboratory needs, medication and formulation, pharmacy or insurance coverage, and follow-up plan. AlyneMD reviews the expected treatment and monitoring costs before therapy begins.
There is no good evidence that compounded bioidentical hormones are inherently safer or more effective than FDA-approved hormone therapy. When an FDA-approved formulation can meet the clinical need, it is generally preferred. Pellet therapy also has unique limitations because the dose cannot be easily adjusted or removed once implanted.
.svg)
